Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more
Vectus Biosystems Ltd - Asset Resilience Ratio
Vectus Biosystems Ltd (VBS) has an Asset Resilience Ratio of 2.18% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2020)
This chart shows how Vectus Biosystems Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Vectus Biosystems Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$70.00K | 2.18% |
| Total Liquid Assets | AU$70.00K | 2.18% |
Asset Resilience Insights
- Limited Liquidity: Vectus Biosystems Ltd maintains only 2.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vectus Biosystems Ltd Industry Peers by Asset Resilience Ratio
Compare Vectus Biosystems Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Vectus Biosystems Ltd (2013–2020)
The table below shows the annual Asset Resilience Ratio data for Vectus Biosystems Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-06-30 | 90.60% | AU$2.72 Million | AU$3.00 Million | +4.48pp |
| 2016-06-30 | 86.11% | AU$4.03 Million | AU$4.68 Million | +85.82pp |
| 2015-06-30 | 0.29% | AU$33.99K | AU$11.73 Million | -77.53pp |
| 2013-06-30 | 77.82% | AU$1.16 Million | AU$1.49 Million | -- |